|
|
TechnoVax and its team of scientists have developed a new way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle (VLP) vaccines using a cell-based manufacturing system.
One of the most exciting aspects of the TechnoVax VLP technology lies in its versatility, which allows for the development of single, polyvalent or combination vaccines that carry the antigen (s) to protect against epidemic strains of respiratory viruses, emerging viruses such as avian influenza (distinct antigenic variants) SARS and other bioterrorism agents. Vaccines developed with TechnoVax’s VLP technology also have the potential to be used as prophylactic or therapeutic treatments for HIV and cancer.
In the medium term TechnoVax plans to extend its technology platform to target many diseases where no vaccine is currently available.
|
Presentación en Español